| Title: |
Pulmonary arterial hypertension in systemic lupus erythematosus: Identification of risk factors and haemodynamics characteristics in a multicentre retrospective cohort |
| Authors: |
Marasco E.; Düsing C.; Keymel S.; Bortoluzzi A.; Bracaglia C.; Canuet M.; Cavazzana I.; Chehab G.; Codullo V.; Fischer R.; Franceschini F.; Fredi M.; Ghio S.; Keller L.; Meyer A.; Montecucco C.; Richter J.; Riou M.; Sahin S.; Sander O.; Schwarting A.; Scirè C. A.; Silvagni E.; Triantafyllias K.; Zanframundo G.; Cavagna L.; Schneider M. |
| Contributors: |
Marasco, E; Düsing, C; Keymel, S; Bortoluzzi, A; Bracaglia, C; Canuet, M; Cavazzana, I; Chehab, G; Codullo, V; Fischer, R; Franceschini, F; Fredi, M; Ghio, S; Keller, L; Meyer, A; Montecucco, C; Richter, J; Riou, M; Sahin, S; Sander, O; Schwarting, A; Scirè, C; Silvagni, E; Triantafyllias, K; Zanframundo, G; Cavagna, L; Schneider, M |
| Publisher Information: |
BMJ Publishing Group; GB |
| Publication Year: |
2025 |
| Collection: |
Università degli Studi di Milano-Bicocca: BOA (Bicocca Open Archive) |
| Subject Terms: |
Lupus Erythematosus; Systemic; Pulmonary Arterial Hypertension; Risk Factor |
| Description: |
Objectives The aim of our work was to identify specific patterns in clinical features and nailfold capillary changes that may help in screening for pulmonary arterial hypertension (PAH) in patients with systemic lupus erythematosus (SLE). Methods We identified patients with SLE and type I PAH (n=20) without other connective tissue diseases and collected demographic, clinical and laboratory features. We selected as controls patients with SLE who underwent cardiopulmonary screening to exclude PAH (n=87): we collected demographic, clinical and laboratory features and performed nailfold videocapillaroscopy (NVC). Results All patients with SLE-PAH were women; age and disease duration were not different from patients with SLE without PAH. Lupus anticoagulant (LAC)+and anti-ribonucleoprotein (RNP)+were more prevalent in patients with SLE-PAH (respectively, PAH 45.0% vs no-PAH 20.5%, p=0.042; PAH 45.0% vs no-PAH 19.5%, p=0.035). No differences were observed for anti-Sm, anti-Ro, anti-La and anti-cardiolipin and anti-beta2GPI antibodies. Among clinical features, mucocutaneous and central nervous system involvement were more prevalent in patients with SLE-PAH than in SLE controls (respectively, PAH 65.0% vs no-PAH 34.5%, p=0.024; PAH 25.0% vs no-PAH 8.0%, p=0.046). Raynaud's phenomenon (RP) was more prevalent in patients with SLE-PAH than in SLE controls (PAH 60.0% vs no-PAH 13.8%, p |
| Document Type: |
article in journal/newspaper |
| File Description: |
ELETTRONICO |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/40514051; info:eu-repo/semantics/altIdentifier/wos/WOS:001510015000001; volume:12; issue:1; journal:LUPUS SCIENCE & MEDICINE; https://hdl.handle.net/10281/596674 |
| DOI: |
10.1136/lupus-2024-001471 |
| Availability: |
https://hdl.handle.net/10281/596674; https://doi.org/10.1136/lupus-2024-001471 |
| Rights: |
info:eu-repo/semantics/openAccess ; license:Creative Commons ; license uri:http://creativecommons.org/licenses/by-nc/4.0/ |
| Accession Number: |
edsbas.7CCD108D |
| Database: |
BASE |